Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q

Authors: Komal Jhaveri, X.V. Wang, Vicky Makker, Shiuh‐Wen Luoh, Edith P. Mitchell, James A. Zwiebel, Elad Sharon, Robert J. Gray, S. Li, Lisa M. McShane, Larry Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, A.P. Chen, Keith T. Flaherty - Annals of Oncology 2019 cited by 143